ARCHIVES

Campath Improves PFS In B-Cell CLL In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 30 No. 1 | January 26, 2007

Download PDF Visit The Full Archive

Related Articles

NCI director says rules hurt retention, recruitment, cites Liotta’s departure.

April 8, 2005

Kadcyla Extends Median PFS In Open-Label Phase III Trial

October 25, 2013

Trials Approved by NCI CTEP For the Month of December

December 30, 2011

Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia

October 31, 2003

US Oncology Inc. Asked For Drug Purchase Information.

July 4, 2003

NCI-Approved Clinical Trials Listed For January

January 28, 2005